Antibiotics, antivirals and antifungals for the eye
Eye infections range from a self-limiting conjunctivitis to an endophthalmitis that can destroy the eye in a day, and the choice of drug and route changes completely between them. This lesson goes through the antibacterial classes used on and in the eye, then the antivirals, antifungals and anti-amoebic agents. For each it gives the mechanism, the organisms covered, where it is used and the hazards worth knowing. The diseases themselves are taught in the cornea and vitreoretinal chapters.
Matching the route to the infection
The first decision is where the organism is, because that decides how the drug must be given. An infection of the conjunctiva or lid margin sits on the surface, where a drop or ointment reaches a very high concentration. An infection in the cornea needs the same route but far more often, because the drug has to soak into the stroma against constant washout by tears. An infection inside the eye is beyond the reach of drops, and antibiotics given by mouth or vein cross the blood-ocular barriers poorly, so the drug is injected directly into the vitreous.
| Infection | Route | Typical regimen |
|---|---|---|
| Bacterial conjunctivitis | Topical | Often none needed; chloramphenicol if severe |
| Blepharitis | Topical ointment to lid margin; oral tetracycline for posterior disease | Courses repeated as needed |
| Bacterial keratitis | Intensive topical | Fluoroquinolone drops as often as every 15 minutes at first |
| Prevention of endophthalmitis | Intracameral | Cefuroxime 1 mg at the end of cataract surgery |
| Endophthalmitis | Intravitreal | Vancomycin with ceftazidime |
| Orbital cellulitis | Intravenous | Broad-spectrum systemic antibiotics |
The BNF notes that most acute bacterial conjunctivitis is self-limiting and resolves within 5 to 7 days without treatment. Antibacterial drops are for severe infection or where rapid resolution is needed. Keratitis and endophthalmitis are different: both need same-day specialist treatment.
Antibacterials for the surface
Chloramphenicol is the standard first topical antibiotic in UK primary care and is also sold over the counter. It blocks protein synthesis at the bacterial 50S ribosomal subunit and is bacteriostatic. The BNF calls it a potent broad-spectrum antibiotic. It covers the usual causes of conjunctivitis, which the BNF lists as Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae, but UK product information states that it does not give adequate cover against Pseudomonas aeruginosa. The BNF regimen is one drop every 2 hours at first, reduced as the infection comes under control, or ointment three or four times daily, continued for 48 hours after healing.
Systemic chloramphenicol can cause aplastic anaemia and, in newborns, the grey baby syndrome. The amount absorbed from eye drops is tiny, and the BNF lists bone marrow disorders only as a side effect of unknown frequency with eye use. It does advise avoiding the drops in pregnancy unless essential.
Fusidic acid 1% is a viscous drop used twice daily. It is licensed for staphylococcal eye infections, which makes it an alternative when chloramphenicol is unsuitable, but its spectrum is narrower.
Azithromycin, a macrolide, also acts on the 50S subunit. It is the drug for chlamydial eye disease. As drops it is licensed twice daily for 3 days for purulent bacterial and trachomatous conjunctivitis. By mouth it is the treatment the World Health Organization recommends for trachoma. Oral tetracyclines such as doxycycline are used for posterior blepharitis in patients over 12 years, as much for their effect on meibomian gland secretions and inflammation as for killing bacteria.
Antibacterials for keratitis and inside the eye
Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin) inhibit bacterial DNA gyrase and topoisomerase IV, so DNA cannot be unwound and copied. They are bactericidal, broad in spectrum, penetrate the cornea well and cover Pseudomonas aeruginosa, the organism most feared in contact lens wearers. A single fluoroquinolone is therefore the usual first treatment for bacterial keratitis. The BNF regimen for ciprofloxacin in corneal ulcer shows how intensive this is: every 15 minutes for 6 hours, every 30 minutes for the remainder of day 1, hourly on day 2, then every 4 hours, day and night. Ciprofloxacin can leave white crystalline deposits in the ulcer bed, which clear after treatment stops.
Aminoglycosides (gentamicin, tobramycin) bind the 30S ribosomal subunit and are bactericidal against Gram-negative bacilli including Pseudomonas. For a large or sight-threatening ulcer some units use fortified drops, made up at a higher concentration than commercial products: an aminoglycoside at around 15 mg/mL for Gram-negative cover, alternated hourly with a second fortified drug for Gram-positive cover, such as a cephalosporin or vancomycin. Aminoglycosides are toxic to the corneal epithelium, and to the retina if injected into the vitreous, where they have caused macular infarction.
Cephalosporins are beta-lactams that block cell wall synthesis. Two matter. Cefuroxime is injected into the anterior chamber (1 mg, intracameral) at the end of cataract surgery to prevent endophthalmitis. Ceftazidime is a third-generation agent with strong Gram-negative activity, including Pseudomonas, and is one half of the standard intravitreal pair.
Vancomycin is a glycopeptide that blocks cell wall synthesis by a different step and covers Gram-positive organisms including resistant staphylococci. In acute endophthalmitis the vitreous is sampled and then injected with vancomycin 1 mg and ceftazidime 2 mg, each in 0.1 mL. Some protocols give ceftazidime as 2.25 mg. Between them the two drugs cover nearly all likely organisms. Most culture-positive cases after cataract surgery are caused by Gram-positive bacteria, which is why vancomycin is essential.
| Class | Target | Strength | Main eye use |
|---|---|---|---|
| Chloramphenicol | 50S ribosome | Broad; not Pseudomonas | Conjunctivitis, prophylaxis after minor injury or surgery |
| Fusidic acid | Protein synthesis | Staphylococci | Conjunctivitis, blepharitis |
| Fluoroquinolones | DNA gyrase | Broad, including Pseudomonas | Bacterial keratitis |
| Aminoglycosides | 30S ribosome | Gram-negative, including Pseudomonas | Fortified drops for severe keratitis |
| Cephalosporins | Cell wall | Depends on generation | Intracameral cefuroxime; intravitreal ceftazidime |
| Glycopeptides | Cell wall | Gram-positive, including resistant staphylococci | Intravitreal vancomycin |
| Macrolides | 50S ribosome | Chlamydia | Trachoma, chlamydial conjunctivitis |
Antivirals
Aciclovir is a prodrug that is inactive until it is phosphorylated. The first phosphate is added by thymidine kinase, an enzyme made by herpes simplex and varicella-zoster viruses but not used in the same way by human cells. The activated drug then blocks viral DNA polymerase. Because activation happens almost only inside infected cells, aciclovir is selective and has little toxicity. This also means it does nothing against latent virus in the ganglion, which is not replicating, so it treats attacks without curing the infection.
For herpes simplex epithelial keratitis (a dendritic ulcer) the BNF regimens are aciclovir eye ointment five times a day, continued for at least 3 days after healing, or ganciclovir eye gel five times a day until healed and then three times a day for a further 7 days. Oral aciclovir or valaciclovir is used for herpes zoster ophthalmicus and as long-term prophylaxis against recurrent herpes simplex keratitis.
Cytomegalovirus lacks the thymidine kinase that activates aciclovir well, so aciclovir is a poor drug for it. Ganciclovir, and its oral prodrug valganciclovir, are activated by a different viral kinase and are the treatment for cytomegalovirus retinitis, given systemically or by intravitreal injection. Systemic ganciclovir suppresses the bone marrow, causing neutropenia, anaemia and thrombocytopenia.
Antifungals
Fungal cell membranes contain ergosterol where human membranes contain cholesterol, and both main classes of antifungal exploit that difference. Polyenes bind to ergosterol and punch holes in the membrane. Azoles block the enzyme that makes ergosterol.
- Natamycin 5% is a polyene and the usual first topical drug for filamentous fungi such as Fusarium and Aspergillus, the organisms that follow injury with plant material.
- Amphotericin B, another polyene, is made up as a 0.15% drop and is used particularly for yeasts such as Candida. It is also given intravitreally (5 to 10 micrograms) for fungal endophthalmitis.
- Voriconazole is an azole given as a 1% drop, by mouth, by injection into the corneal stroma or into the vitreous. Its advantage is good penetration into the eye when given orally.
Antifungals penetrate the cornea poorly and fungi grow slowly, so treatment is hourly at first and continues for weeks to months. The BNF points out that antifungal eye preparations are not generally available commercially in the UK. They are obtained as specially manufactured products through hospital eye units. Steroids make fungal keratitis worse and are avoided.
Anti-amoebic agents
Acanthamoeba exists as an active trophozoite and as a dormant, double-walled cyst. Most antimicrobials kill the trophozoite. The cyst is the problem, because it survives treatment and reactivates. The drugs that work are antiseptics, not conventional antibiotics.
- Biguanides: polihexanide, also called polyhexamethylene biguanide or PHMB, and chlorhexidine. These damage cell membranes and are the mainstay because they kill cysts.
- Diamidines: propamidine and hexamidine, often added to a biguanide.
The traditional combination is PHMB 0.02% with propamidine 0.1%. A randomised trial found that polihexanide 0.08% alone was as effective as that combination, with a cure rate of about 86%. Drops start hourly and are tapered over many months. Steroids are generally avoided, and are considered only after at least two to three weeks of anti-amoebic treatment in selected inflamed eyes.
Summary
- Surface infections are treated with drops, keratitis with intensive drops, and endophthalmitis with intravitreal injection.
- Chloramphenicol is the first-line topical antibiotic for bacterial conjunctivitis in the UK when treatment is needed.
- Fluoroquinolones cover Pseudomonas and are the usual first drug for bacterial keratitis, especially in contact lens wearers.
- Aminoglycosides cover Gram-negative organisms and are toxic to the corneal epithelium and the retina.
- Intracameral cefuroxime 1 mg at the end of cataract surgery prevents endophthalmitis.
- Endophthalmitis is treated with intravitreal vancomycin for Gram-positive and ceftazidime for Gram-negative organisms.
- Aciclovir is activated by viral thymidine kinase and inhibits viral DNA polymerase; it does not clear latent virus.
- Ganciclovir treats cytomegalovirus retinitis and suppresses the bone marrow when given systemically.
- Natamycin is the usual first drug for filamentous fungal keratitis; amphotericin B is used for Candida.
- Acanthamoeba cysts are treated with a biguanide such as polihexanide or chlorhexidine for months.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.